Immunomodulatory effects of lenvatinib plus anti‐PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d4560529e249">Lenvatinib is an effective drug in advanced HCC. Its combination with the anti-PD1 (programmed cell death protein 1) immune checkpoint inhibitor, pembrolizumab, has generated encouraging results in phase Ib and is currently being tested in phase III trials. Here, we aimed to explore the molecular and immunomodulatory effects of lenvatinib alone or in combination with anti-PD1. </p>

Related collections

Author and article information

Contributors

Laura Torrens: (View ORCID Profile)

Ugne Balaseviciute: (View ORCID Profile)

Catherine E. Willoughby: (View ORCID Profile)

Jordi Abril‐Fornaguera: (View ORCID Profile)

Josep M. Llovet: (View ORCID Profile)

Journal

Title: Hepatology

Abbreviated Title: Hepatology

Publisher: Wiley

ISSN (Print): 0270-9139

ISSN (Electronic): 1527-3350

Publication date (Electronic): June 22 2021

Affiliations

[1 ]Mount Sinai Liver Cancer Program Division of Liver Diseases Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York USA

[2 ]Translational Research in Hepatic Oncology, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)‐Hospital Clínic Universitat De Barcelona Catalonia Spain

[3 ]Hepatology Section, Gastroenterology Department Parc de Salut Mar IMIM (Hospital del Mar Medical Research Institute) Barcelona Catalonia Spain

[4 ]Newcastle Fibrosis Research Group Biosciences Institute Newcastle University Newcastle upon Tyne UK

[5 ]Institució Catalana De Recerca i Estudis Avançats Barcelona Catalonia Spain

Article

DOI: 10.1002/hep.32023

PubMed ID: 34157147

SO-VID: 60727297-7634-4742-9c7d-91078282d14e

License:

http://onlinelibrary.wiley.com/termsAndConditions#vor

http://doi.wiley.com/10.1002/tdm_license_1.1

History

Data availability:

Comments

Comment on this article

scite_

Cited by 59

See all cited by

- Version 1